A Phase II Open Label Randomised Multicentric Study in Patients With Unresectable Glioblastoma Using Neo-adjuvant Treatment With Two Cycles of Temozolomide Previous to Temozolomide Plus Radiation Therapy and Adjuvant Temozolomide vs. Neo-adjuvant Treatment With Two Cycles of Temozolomide Plus Bevacizumab Previous to Temozolomide, Bevacizumab and Radiation Therapy and Adjuvant Temozolomide.
Phase of Trial: Phase II
Latest Information Update: 01 May 2016
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- 10 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 22 Dec 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Primary endpoint 'Objective-clinical-response-rate' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History